Drug intelligence / Profile preview

GT300

Development stage: Phase 1
Lead developer: Generian Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

GT300 (also referred to as GT-300 or GT 300) is an orally available small molecule drug candidate developed by Generian Pharmaceuticals. It is being investigated primarily for the treatment of Lewy body disease and other nervous system diseases. The mechanism of action has not been fully defined but exploratory studies have evaluated its effects on the autophagy-lysosomal pathway. As of February 2024, no development beyond preclinical or early clinical phases has been reported for Lewy body disease[1][2][4]. A phase I study in healthy subjects was planned to assess safety and pharmacokinetics[1][7].

Targets

TFEB (Transcription factor EB)

Beyond the preview

Go deeper on GT300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT300.

Explore the full profile